Timothy Eugene Sullivan insider trades: Apellis Pharmaceuticals (APLS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Timothy reports to the SEC
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | APLS | ↓ Sell | 10,287 | $21.77 | $224K | Direct | Jan 23, 2026 (1d) |
| Jan 20, 2026 | APLS | ↓ Sell | 2,892 | $19.79 | $57K | Direct | Jan 21, 2026 (1d) |
| Jan 13, 2026 | APLS | ↓ Sell | 3,856 | $22.19 | $86K | Direct | Jan 15, 2026 (2d) |
| Oct 21, 2025 | APLS | ↓ Sell | 10,000 | $28.03 | $280K | Direct | Oct 23, 2025 (2d) |
| Sep 8, 2025 | APLS | ↓ Sell | 32,729 | $27.86 | $912K | Direct | Sep 10, 2025 (2d) |
| Sep 8, 2025 | APLS | ↓ Sell | 10,000 | $27.83 | $278K | The Timothy E Sullivan Irrevocable Trust | Sep 10, 2025 (2d) |
| Jan 29, 2025 | APLS | ↓ Sell | 546 | $29.52 | $16K | Direct | Jan 30, 2025 (1d) |
| Jan 22, 2025 | APLS | ↓ Sell | 3,088 | $30.43 | $94K | Direct | Jan 23, 2025 (1d) |
| Jan 17, 2025 | APLS | ↓ Sell | 1,730 | $29.96 | $52K | Direct | Jan 21, 2025 (4d) |
| Jan 13, 2025 | APLS | ↓ Sell | 2,170 | $28.70 | $62K | Direct | Jan 14, 2025 (1d) |
| Apr 1, 2024 | APLS | ↓ Sell | 4,000 | $58.66 | $235K | Direct | Apr 2, 2024 (1d) |
| Mar 1, 2024 | APLS | ↓ Sell | 6,000 | $63.22 | $379K | Direct | Mar 5, 2024 (4d) |
| Feb 12, 2024 | APLS | ↓ Sell | 1,431 | $67.77 | $97K | Direct | Feb 13, 2024 (1d) |
| Jan 29, 2024 | APLS | ↓ Sell | 906 | $64.14 | $58K | Direct | Jan 31, 2024 (2d) |
| Jan 22, 2024 | APLS | ↓ Sell | 3,551 | $65.00 | $231K | Direct | Jan 23, 2024 (1d) |
| Jan 16, 2024 | APLS | ↓ Sell | 2,235 | $66.81 | $149K | Direct | Jan 17, 2024 (1d) |
| Nov 30, 2023 | APLS | ↓ Sell | 14,158 | $54.73 | $775K | Direct | Dec 1, 2023 (1d) |
| Jul 3, 2023 | APLS | ↓ Sell | 6,779 | $89.97 | $610K | Direct | Jul 6, 2023 (3d) |
| Jun 5, 2023 | APLS | ↓ Sell | 69,779 | $88.80 | $6.2M | Direct | Jun 6, 2023 (1d) |
| Aug 29, 2019 | APLS | ↑ Buy10b5-1 | 11,699 | $29.71 | $348K | Direct | Sep 3, 2019 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other APLS insiders
Open-market trades in the last 12 months
About Timothy Eugene Sullivan's insider trades
Timothy Eugene Sullivan is Chief Financial Officer at Apellis Pharmaceuticals (APLS). Since Aug 29, 2019, Timothy has reported 1 open-market purchase worth $348K and 19 sales worth $10.8M on SEC Form 4. In the last 12 months: 3 sales ($367K).
Their filings also include grants and awards (12 filings), option exercises (9 filings), shares withheld for taxes (7 filings), gifts (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APLS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.